Sage Therapeutics (NASDAQ:SAGE) has been reviewed by 5 analysts in the last three months, showing diverse opinions from bullish to bearish. The recent evaluations indicate a shift towards a more positive outlook, with an average 12-month price target of $26.2, up 16.44% from the previous $22.50. Analysts from JP Morgan, RBC Capital, Morgan Stanley, and HC Wainwright & Co. have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. Sage Therapeutics, a clinical-stage biopharmaceutical company, has shown significant revenue growth of 2621.54% as of December 31, 2023, and has a strong financial health with impressive ROE and ROA figures.